Accumulate Call for Ipca

Prabhudas Lilladher recommended an accumulate call on Ipca Laboratories with a target price of Rs 1008. Let’s take a quick look at Prabhudas Lilladher’s research report on Ipca.
Research Report on Ipca Laboratories:
According to Prabhudas Lilladher’s research reports, the stock’s sales, EBITDA and PAT grew by 4%, 36%, and 50% respectively. The Q1FY20 results were beyond our estimates. On the other hand, the stock IPCA took advantage of the high demand and price of Sartan APIs especially the EU in global markets due to contamination issues. The Sartan APIs’ contribution increased to 30% from 25%. As a result it, higher material costs and lower gross margin by 360bps QoQ.
Outlook:
We maintained our accumulate rating on Ipca Laboratories with a target price of Rs 1008. As per our current estimation, the upside potential is at 8%.
Disclaimer: The perspectives and investment tips are given in this section are the expert’s own and not that of the website or its management. We encourage clients to check with certified experts before taking any position in the stocks/shares mentioned.